22 May 2013
Keywords: guilford, restarts, aquavan, program, pharmaceuticals, usa, says
Article | 25 April 2005
Guilford Pharmaceuticals of the USA says that it can continue clinical development of its lead candidate, Aquavan Injection (GPI 15715), a
Enjoying this article? To continue reading you need to login or subscribe.
Subscriptions are £60 per month, pay as you go.
Find out more details.
25 April 2005
21 May 2013
© 2013 thepharmaletter.com